Prevalence, etiology, and treatment of depression in Parkinson's disease

scientific article (publication date: August 2003)

Prevalence, etiology, and treatment of depression in Parkinson's disease is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/S0006-3223(03)00530-4
P3181OpenCitations bibliographic resource ID562465
P698PubMed publication ID12893111

P50authorMahlon DeLongQ15374218
William M. McDonaldQ67228349
P2093author name stringIrene H Richard
P2860cites workA rating scale for depressionQ24564540
An Inventory for Measuring DepressionQ26778503
Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studiesQ28140388
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressantQ28324024
Nigral endothelial dysfunction, homocysteine, and Parkinson's diseaseQ28369292
A New Depression Scale Designed to be Sensitive to ChangeQ29614720
Fluoxetine in Parkinson's diseaseQ67226561
In vivo stereological assessment of caudate volume in man: effect of normal agingQ68592055
Depression in Parkinson's diseaseQ68694013
Fluoxetine and extrapyramidal side effectsQ69414840
Parkinson's disease, depression, and the on-off phenomenonQ69940431
Parkinson's disease camouflaging early signs of hypothyroidismQ70518079
Does fluoxetine aggravate Parkinson's disease? A pilot prospective studyQ72000199
Parkinson's disease and depression: the relationship to disability and personalityQ72090835
Dopamine and depressionQ72222122
Parkinsonism exacerbated by paroxetineQ72884150
Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemesQ73776786
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depressionQ74446178
Minor and subsyndromal depression: functional disability worth treatingQ77873245
IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDYQ78407425
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonographyQ30495686
Transcranial magnetic stimulation: applications in neuropsychiatryQ30572921
Magnetic resonance in patients with affective illnessQ30997803
Parkinson's disease and depression: psychometric properties of the Beck Depression InventoryQ33630514
Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?Q33660662
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?Q33733822
Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporterQ33873790
Risk factors for dementia, depression and psychosis in long-standing Parkinson's diseaseQ33917650
Functional changes of the basal ganglia circuitry in Parkinson's disease.Q33924857
Non-dopaminergic drug treatment of Parkinson's diseaseQ34240947
Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's diseaseQ34305931
Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidityQ34646047
Applications of transcranial magnetic stimulation in movement disordersQ35000091
Depression and Parkinson's disease: a reviewQ35313173
Homocysteine, folate, methylation, and monoamine metabolism in depressionQ35458595
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled studyQ35467921
Effect of age at onset on frequency of depression in Parkinson's diseaseQ36864189
Cognitive impairments and depression in Parkinson's disease: a follow up studyQ36938802
A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's diseaseQ36961731
The etiology of depression in Parkinson's disease patientsQ37556320
Coexisting dementia and depression in Parkinson's diseaseQ38209726
Neuropsychological and psychiatric sequelae of pallidotomy for PD: clinical trial findingsQ38435548
Neuropsychological impairment in Parkinson's disease with and without depressionQ38462009
Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson diseaseQ40621648
The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disabilityQ40809937
Depressive symptoms in Parkinson's disease: a comparison with disabled control subjectsQ41197355
Anxiety and Parkinson's diseaseQ41442784
Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo StudyQ41607274
Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled studyQ41787776
Increase of Parkinson disability after fluoxetine medicationQ42289259
Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat.Q42484629
The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics.Q42509207
SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.Q42655854
Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.Q42691933
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.Q43520287
The correlation of depression with functional activity in Parkinson's diseaseQ43538074
Antecedent clinical features associated with dementia in Parkinson's diseaseQ43577797
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease.Q43590767
In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's diseaseQ43670960
Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's diseaseQ43974492
Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's diseaseQ43977645
Homocysteine in neuropsychiatric disorders of the elderlyQ44131619
Depressive symptoms as relative and attributable risk factors for first-onset major depressionQ44274354
???Q64862715
The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopaQ45711592
Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general populationQ46068701
ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptidesQ47994670
Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients.Q48448624
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of ratsQ48458364
Depression and Parkinson's disease: a new look at an old problemQ48497066
Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open studyQ48552742
The neuropathologic basis of different clinical subgroups of Parkinson's diseaseQ48633612
The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach.Q48637566
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological studyQ48661239
Altered serotonin metabolism in depressed patients with parkinson's diseaseQ48680548
Risk factors for depression in Parkinson diseaseQ48719363
Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesionsQ48738450
The motor performance test series in Parkinson's disease is influenced by depressionQ48786674
Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's diseaseQ48939047
Depression and medical illness in late life: report of a symposiumQ50107221
An estimate of the incidence of depression in idiopathic Parkinson's disease.Q50543153
Effectiveness of ECT in patients with parkinsonism.Q50885058
Depression and disability in Parkinson's disease.Q51003628
Factors impacting on quality of life in Parkinson's disease: results from an international survey.Q51055467
Relationship between mood and motor fluctuations in Parkinson's disease.Q51070527
Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: Preliminary findingsQ51124819
Mood changes and "on-off" phenomena in Parkinson's disease.Q51170704
Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.Q51973773
Maintenance ECT in Parkinson's disease.Q51975587
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.Q52002538
The occurrence of depression in Parkinson's disease. A community-based study.Q52009711
Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease.Q52033168
Depression, intellectual impairment, and Parkinson disease.Q52101557
A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.Q52864240
The quality of life in Parkinson's disease.Q53524833
Sertraline for the treatment of depression in Parkinson's disease.Q53964557
S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial.Q55034448
Bupropion in Parkinson's disease.Q55062563
Tolerability of paroxetine in Parkinson's disease: A prospective studyQ57203470
Transient Acute Depression Induced by High-Frequency Deep-Brain StimulationQ60490586
Paroxetine in Parkinson's disease: effects on motor and depressive symptomsQ64765320
Depression in Parkinson's diseaseQ64785206
Thyroid function in Parkinson diseaseQ64787317
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPAQ64791376
Keeping depression at bay helps patients with Parkinson diseaseQ64854681
Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case seriesQ64866414
Elevated plasma levels of homocysteine in Parkinson's diseaseQ64867918
Depression in classic versus akinetic-rigid Parkinson's diseaseQ64922801
Cognitive functions in major depression and Parkinson diseaseQ64972083
Desipramine in treatment of Parkinson's disease. A placebo-controlled studyQ67215620
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectParkinson's diseaseQ11085
P304page(s)363-75
P577publication date2003-08-01
P1433published inBiological PsychiatryQ4914961
P1476titlePrevalence, etiology, and treatment of depression in Parkinson's disease
P478volume54

Reverse relations

cites work (P2860)
Q64806377Q64806377
Q64864842Q64864842
Q36307871A matter of motion or an emotional matter? Management of depression in Parkinson's disease
Q37275088Alexithymia and apathy in Parkinson's disease: neurocognitive correlates
Q37605604Altered directional connectivity between emotion network and motor network in Parkinson's disease with depression
Q36255233Alternatives to levodopa in the initial treatment of early Parkinson's disease
Q48359779Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats
Q48250330Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain
Q27318295Apathy, Novelty Processing, and the P3 Potential in Parkinson's Disease
Q35189606Assessing depression and factors possibly associated with depression during the course of Parkinson's disease.
Q37210088Assessment of depression in three medically ill, elderly populations: Alzheimer's disease, Parkinson's disease, and stroke
Q36969544Associated and predictive factors of depressive symptoms in patients with Parkinson's disease.
Q40765887Associations of pain and depression with marital status in patients diagnosed with Parkinson's disease.
Q36140767Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature
Q82029017Chapter 50 Pain in Parkinson's disease
Q43165318Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons
Q35946064Cognition in mania and depression: psychological models and clinical implications
Q92968669Comorbid Depression and Psychosis in Parkinson's Disease: A Report of 62,783 Hospitalizations in the United States
Q37973611Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.
Q47968188Cortical thinning in drug-naive Parkinson's disease patients with depression.
Q90116092Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test
Q48405825Deep brain stimulation for the treatment of Parkinson's disease.
Q36446704Depression and coronary heart disease
Q48452383Depression and intelligence in patients with Parkinson's disease and deep-brain stimulation
Q42646021Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).
Q43835412Depression in Parkinson's disease. Assessment and treatment
Q50194256Depression in patients with Parkinson's disease and the associated features
Q37225955Depression in the medically ill: diagnostic and therapeutic implications
Q34578187Depression rating scales in Parkinson's disease: critique and recommendations
Q47759633Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders.
Q36738506Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses.
Q24815683Developmental pesticide models of the Parkinson disease phenotype
Q47642861Diagnostic Validity and Factor Analysis of Montgomery-Asberg Depression Rating Scale in Parkinson Disease Population
Q40189130Discordance Between Physician Assessment and Patient-Reported Depressive Symptoms in Parkinson Disease
Q37685695Dopamine receptor agonists and depression in Parkinson's disease
Q64235467Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease
Q34102890Effects of depression and social support on comprehension and recall of informed consent information among Parkinson disease patients and their caregivers
Q36744761Emotional state affects gait initiation in individuals with Parkinson's disease
Q47950883Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes
Q33634151Frequency specific brain networks in Parkinson's disease and comorbid depression
Q46800578Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions
Q37156009Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18
Q40719044Hematopoietic cytokines as therapeutic players in early stages Parkinson's disease.
Q43037703Illness comorbidity as a biomarker?
Q45776139Impact of Depression on Hospitalization and Related Outcomes for Parkinson's Disease Patients: A Nationwide Inpatient Sample-Based Retrospective Study
Q41469238Impact of ethnicity on mood disorders in Parkinson's disease
Q36696078Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
Q45124937Influence of Mild Cognitive Impairment, Depression, and Anxiety on the Quality of Life of Patients with Parkinson Disease
Q43622007Influence of continuous infusion of interleukin-1beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression
Q37315808Introduction: chronic medical conditions and depression--the view from primary care
Q92591063Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype
Q24629770MAO-inhibitors in Parkinson's Disease
Q48483209MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions.
Q34302897Major depressive disorder in Parkinson's disease: a cross-sectional study from Sri Lanka
Q28066691Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Q73739199Mood disorders and medical illness: a major public health problem
Q33303267Motor deficits and altered striatal gene expression in aphakia (ak) mice
Q36615980Movement disorders: neurodevelopment and neurobehavioural expression
Q38176606Neural and behavioral substrates of subtypes of Parkinson's disease
Q37071589Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease
Q36525764Non-motor aspects of Parkinson's disease.
Q47826150Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Q94371699Parkinson's disease
Q28264391Parkinson's disease
Q36567378Paroxetine for somatic pain associated with physical illness: a review
Q52311656Patterns and Predictors of Depression Treatment among Older Adults with Parkinson's Disease and Depression in Ambulatory Care Settings in the United States.
Q41838690Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease
Q46589346Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study
Q41110293Prevalence of depression in Parkinson's disease in a Lebanese tertiary clinic.
Q50890389Prevalence of depression in a 12-month consecutive sample of patients with ALS.
Q35043972Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder
Q26766021Psychosocial Modulators of Motor Learning in Parkinson's Disease
Q36006174Qualitative Characteristics of Depression in Parkinson's Patients and Controls
Q45352049Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease
Q48401125Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression.
Q35893872Retracted: Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice
Q48128398Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism
Q33715050Screening for Depressive Disorder in Elderly Patients with Chronic Physical Diseases Using the Patient Health Questionnaire-9.
Q36679249Serotonergic vulnerability and depression: assumptions, experimental evidence and implications.
Q46252066Sertraline in the treatment of depressive disorders in patients with Parkinson's disease
Q64926088Simultaneous Detection of Dopamine and Serotonin-A Comparative Experimental and Theoretical Study of Neurotransmitter Interactions.
Q60053953Sleep Quality, Depression, and Quality of Life After Bilateral Anodal Transcranial Direct Current Stimulation in Patients with Parkinson's Disease
Q80351905Sleep disorders in Parkinson's disease
Q30480822Startle reflex hyporeactivity in Parkinson's disease: an emotion-specific or arousal-modulated deficit?
Q48431005Stress exacerbates experimental Parkinson's disease
Q35713356Stress, depression and Parkinson's disease
Q37312897Subthreshold depression in Parkinson's disease
Q48507111The diagnosis and treatment of depression in Parkinson's disease
Q36074454The impact of depressive symptoms in early Parkinson disease
Q48301186The impact of sleep and mood disorders on quality of life in Parkinson's disease patients
Q37129850The patients' perspective: Results of a survey assessing knowledge about and attitudes toward depression in PD
Q36871133The psychomotor theory of human mind.
Q35101458The role of cognitive-behavioural therapy for patients with depression in Parkinson's disease
Q47322917The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson's disease
Q47915497The role of social support in anxiety and depression among Parkinson's disease patients
Q36826802Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders
Q34272602Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease
Q37158450Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?
Q43763804Untreated depressive symptoms among cognitively-intact, community dwelling Filipino patients with Parkinson disease
Q33767361Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease
Q50117645Voluntary Physical Exercise Improves Subsequent Motor and Cognitive Impairments in a Rat Model of Parkinson's Disease
Q33856140What are the causes of late-life depression?
Q48091560White matter microstructure changes in the thalamus in Parkinson disease with depression: A diffusion tensor MR imaging study
Q53427550Zanthoxylum alatum abrogates lipopolysaccharide-induced depression-like behaviours in mice by modulating neuroinflammation and monoamine neurotransmitters in the hippocampus.